119th Congress · House bill · Last action Jul 9, 2026
H.R. 9635In Committee
To amend the Federal Food, Drug, and Cosmetic Act to establish special rules to provide for continued review of human drug and device submissions during a lapse of appropriations, and for other purposes.
Sponsor: Rep. Mullin, Kevin (D-CA)Introduced Jul 9, 2026
✆
In plain English
A plain-English summary isn’t available for this bill yet.
Where it is in the process
✓
Introduced
Jul 9
✓
House committee
Jul 9
3
House floor
-
4
Senate
-
5
Signed
-
What happens next: Sits in committee. Needs a markup or favorable report to advance to the House floor.
Sponsor
KR
Rep. Mullin, Kevin [D-CA-15]
D-CA-15
Cosponsors (0)
No cosponsors yet.
Activity timeline
Jul 9
1d ago
1d ago
Referred to the House Committee on Energy and Commerce.
Jul 9
1d ago
1d ago
Introduced in House
Jul 9
1d ago
1d ago
Introduced in House
Read the bill text
Official text via Congress.gov. Opens in a new tab.
Full action log
All 3 recorded actions since introduction · Source: Congress.gov
Jul 9
HOUSEReferred to the House Committee on Energy and Commerce.
Jul 9
Introduced in House
Jul 9
Introduced in House
Track this bill
Get an alert when it moves to the next stage or gets a vote.